TORONTO, March 27, 2015 /PRNewswire/ - Merus Labs
International Inc. (NASDAQ:MSLI; TSX:MSL) ("Merus" or "the
Company") pleased to announce that Dr. Robert Bloch M.D. will join the Board of
Directors effective today. Dr. Bloch is
a European-based pharmaceutical industry veteran
who has a proven track record of
leading profitable growth in global
markets. Dr. Bloch's expertise in extracting value from
established products and vast business development network is
expected to accelerate Merus' expansion plans.
Dr. Bloch has more than 15 years of
leadership experience with global pharmaceutical companies,
including 7 years at F. Hoffmann-La Roche, based in
Switzerland, most recently as
Vice President, Global Head - Established Products. At Roche he
successfully led a multi-billion USD franchise and had
considerable influence on the company's overall strategic
direction and operating performance. Before joining
Roche, Dr. Bloch advanced through several leadership
roles at Schering-Plough and Wyeth.
Dr. Bloch's extensive experience strengthens Merus' market
knowledge and network in the European
market. Dr. Bloch commented, "I
believe Merus has established a strong
foundation across Europe which sets the path for
sustainable growth and value creation. I am extremely
excited to join the team and
contribute to Merus' growth." Michael Cloutier, Chairman of the
Board added "We are thrilled to have Dr. Bloch join our Board.
His background and market knowledge add new strength to our
European market growth plans."
Merus also announces that Dr. Ulrich
Schoeberl, Head of European Operations will
be leaving on April 30,
2015. "I would like to thank Ulrich for his contributions to
our organization. I know I speak for the Merus team and
Board of Directors in wishing Ulrich success with his future
endeavors," said Barry Fishman,
Chief Executive Officer.
With the Merus European infrastructure solidly in
place and the recent addition of a Head of Supply Chain for
Europe, the commercial role will be re-focused on
pipeline expansion and commercial optimization. Dr. Bloch's
intricate knowledge of the European established products
market will be of great value during this transition
period and beyond, as Merus executes its growth
strategy.
About Merus Labs International Inc.
Merus Labs is a specialty pharmaceutical company focused on
acquiring established products. The Company leverages its expertise
in European and North American markets to optimize the value of
underdeveloped pharmaceutical assets.
Cautionary Statement
Certain statements contained in this press release may
constitute "forward-looking statements" within the meaning of
Section 21E (i) (1) of the United States Securities Exchange Act of
1934. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause Merus' actual
results to be materially different from any future results
expressed or implied by these statements. Such factors include the
following: general economic and business conditions, changes in
demand for Merus' products, changes in competition, the ability of
Merus to complete future acquisitions and to integrate these
acquisitions into its business, Merus' ability to complete future
debt and/or equity financings required to complete future
acquisitions, interest rate fluctuations, currency exchange rate
fluctuations, dependence upon and availability of qualified
personnel and changes in government regulation. In light of these
and other uncertainties, the forward-looking statements included in
this press release should not be regarded as a representation by
Merus that Merus' plans and objectives will be achieved.
These forward-looking statements speak only as of the date of
this press release, and we undertake no obligation to update or
revise the statements.
SOURCE Merus Labs International Inc.